Please assess the completion status of the following clinical trial:

Trial Title: A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is in good health~* Subject's parent/legal guardian can read, understand, and complete the vaccine report card~* Subject is not sexually active and does not plan on becoming sexually active during the study~* Subject has received a documented full primary immunization series against diphtheria, tetanus, and pertussis (not in the last 5 years)~Exclusion Criteria:~* Subject has a known allergy to any vaccine component of V503, Menactra™, or Adacel™~* Subject has a condition that is a contraindication to vaccination with Menactra™ or Adacel™~* Subject has any coagulation disorder~* Female subject is pregnant~* Subject is immunocompromised or immunodeficient~* Subject has had a splenectomy~* Subject has received immunosuppressive therapies in the prior year~* Subject has received any immune globulin product or blood-derived product in the last 3 months~* Subject has received inactivated vaccines within 14 days or live vaccines within 21 days of the first study vaccination~* Subject has received a marketed HPV vaccine or has participation in an HPV vaccine trial~* Subject has received a meningococcal vaccine~* Subject has a fever \>= 100F within 24 hours of vaccination~* Subject has a history of HPV

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Concomitant Vaccination (Type: EXPERIMENTAL): V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
- Non-concomitant Vaccination (Type: EXPERIMENTAL): V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1

Based on this trial design, predict the completion outcome and termination type (if applicable).